Login | Register
Profile | Log out
logo

  • Home
  • News
  • Opinion
  • Other
    • Market Updates
    • Explainers
    • Satire
  • About
  • Contact Us
    • Contact
    • Get Covered
    • Posting Guidelines
  • Subscribe
Submit An Article

Latest Articles

  • Control Bionics Moves to Fully Acquire NeuroBounce Program as EMG-Based Performance Tech Gains Momentum
    Control Bionics Moves to Fully Acquire NeuroBounce Program as EMG-Based Performance Tech Gains Momentum
    • News

  • SKS Technologies Moves to Expand NSW Footprint With Delta Elcom Acquisition
    SKS Technologies Moves to Expand NSW Footprint With Delta Elcom Acquisition
    • News

  • Monash University Partners with HITIQ to Advance Concussion Science Using Smart Mouthguards
    Monash University Partners with HITIQ to Advance Concussion Science Using Smart Mouthguards
    • News

  • Harris Technology targets return to profitability amid surging Refurbished Tech sales and Apple expansion
    Harris Technology targets return to profitability amid surging Refurbished Tech sales and Apple expansion
    • News

  • Pivotal Metals Secures $5.4M to Fast-Track Quebec Drill Program
    Pivotal Metals Secures $5.4M to Fast-Track Quebec Drill Program
    • News

  • Biotron Expands into Anaesthetics with Sedarex Acquisition and $2.5m Raise
    Biotron Expands into Anaesthetics with Sedarex Acquisition and $2.5m Raise
    • News

  • DroneShield Boosts Defence Capability with $13 Million Adelaide R&D Investment
    DroneShield Boosts Defence Capability with $13 Million Adelaide R&D Investment
    • News

  • Stakk Secures T-Mobile Contract to Power Super App Expansion
    Stakk Secures T-Mobile Contract to Power Super App Expansion
    • News

  • Medibank Backs Emyria with Landmark Depression Care Deal
    Medibank Backs Emyria with Landmark Depression Care Deal
    • News

  • NoviqTech Launches Quantum Intelligence Products, Opening Path to Enterprise-Grade Quantum AI
    NoviqTech Launches Quantum Intelligence Products, Opening Path to Enterprise-Grade Quantum AI
    • News

New Zealand Coastal Seafoods reveals sales growth in the face of shareholder pressure

  • In News
  • December 7, 2022
  • Alinda Gupta
New Zealand Coastal Seafoods reveals sales growth in the face of shareholder pressure

Maybe it was too shaken by the retirement of its director or it was really focused on its acquisition of Nine Ocean Group. Either way, for some reason, the secondary producer of nutraceuticals, seafood products and premium marine ingredients New Zealand Coastal Seafoods (ASX: NZS) hid its sales number during the Annual General Meeting, potentially ticking off shareholders.

In the aftermath, The Company reported its sales for October and November “in response to requests at the Company’s recent Annual General Meeting”. NZS achieved sales of $803,5021 during October and November 2022, representing a 25% increase on sales generated across the entirety of the prior comparative period Q2 FY2022 sales, i.e. $644,7961. 

Recent sales momentum has flowed through to total sales of $1.8 million in H1 FY2023 to date, a 27% increase on H1 FY2022 ahead of the busy December 2022 sales period. The strong result has been underpinned by increased sales volumes of the Company’s premium marine products, predominately NZS’ premium dried ling maw, in both branded and bulk purchase formats. 

New Zealand Coastal Seafoods CEO Andrew Peti, commented, “The Company has made very strong progress in recent months, highlighted by a step-change in sales momentum during H1 FY2023. Pleasingly, October and November 2022 sales have already eclipsed the entirety of Q2 FY2022. As travel restrictions associated with the COVID-19 pandemic continue to relax, the Company has been able to undertake a number of business development initiatives across key Australasian markets.” 

He pointed out that the positive results have compelled the Company’s executive team to advance a number of new commercialisation opportunities that remain in the pipeline. New Zealand Coastal Seafoods is an aquaculture company, which provides a range of seafood, including mussels, oysters, maw, marine oil and more. It takes on multiple research and development endeavours to discover new fishing techniques sustainably. 

Though the picture seems pretty, the shareholder insistence on revealing sales data wasn’t completely misplaced. In fact, it probably was a result of the Company reporting a cash burn of about $600k in the September quarter alone, spent largely on product manufacturing. They were reasonably wondering whether the money has made its way back. 

Peti added, “The Board and management have executed a review of the Company’s cost base which has resulted in a reduction of operating expenditure across select business units, to drive group margin growth while also exploring opportunities to accelerate sales through the nutraceutical division.” 

Given that the impending Nine Ocean acquisition is based on shareholder approval, it’s clear that shareholders are keeping close tabs on New Zealand Coastal Seafoods to keep management on their toes.

  • About
  • Latest Posts
Alinda Gupta
Alinda is a Business Reporter for The Sentiment
Latest posts by Alinda Gupta (see all)
  • Ovanti’s iSentric signs contracts worth $14.4m with Malaysian commercial bank - June 27, 2024
  • Baby Bunting fights back from retail downturn with 5-year strategy, includes Gen-Z focus and self-funded growth - June 27, 2024
  • CLEO meets with US FDA to develop strategy for ovarian cancer test launch - June 26, 2024
  •  
  •  
  •  
  •  
  • andrew peti
  • aquaculture
  • New Zealand Coastal Seafoods
  • Nine Ocean Group
  • nzs
  • News

Leave a Comment

You must be logged in to post a comment.

  • About
  • Latest Posts
Alinda Gupta
Alinda is a Business Reporter for The Sentiment
Latest posts by Alinda Gupta (see all)
  • Ovanti’s iSentric signs contracts worth $14.4m with Malaysian commercial bank - June 27, 2024
  • Baby Bunting fights back from retail downturn with 5-year strategy, includes Gen-Z focus and self-funded growth - June 27, 2024
  • CLEO meets with US FDA to develop strategy for ovarian cancer test launch - June 26, 2024

Login or register for free to access unlimited reading

Register Now!
  • About
  • Latest Posts
Alinda Gupta
Alinda is a Business Reporter for The Sentiment
Latest posts by Alinda Gupta (see all)
  • Ovanti’s iSentric signs contracts worth $14.4m with Malaysian commercial bank - June 27, 2024
  • Baby Bunting fights back from retail downturn with 5-year strategy, includes Gen-Z focus and self-funded growth - June 27, 2024
  • CLEO meets with US FDA to develop strategy for ovarian cancer test launch - June 26, 2024
  • News

  • Opinion

  • Satire

  • About

  • Contact Us

  • Subscribe

The content published on this website is solely for general information purposes and is not to be construed as financial advice. Should you seek financial advice you should consult with an appropriately qualified person. Opinions expressed on this site are subject to change without notice and The Sentiment who produced this content is under no obligation to keep the information current. The Sentiment, affiliated companies & associates may have a conflict of interest with companies discussed on the website due to commercial arrangements, for example they may be shareholders in the company, be engaged by them to assist in investor communications or receive commission/brokerage for funds raised.

Copyright © 2020 The Sentiment. All rights reserved.
Subscribe

Enter your email address below to subscribe to The Sentiment’s weekly newsletter, highlighting the top news, research, opinion and satire articles shaping ASX investor sentiment.

The Sentiment respects your privacy and will not spam you. View our privacy policy here.